444158
MDMX Inhibitor, NSC207895
The MDMX Inhibitor, NSC207895 controls the biological activity of MDMX. This small molecule/inhibitor is primarily used for Cancer applications.
别名:
MDMX Inhibitor, NSC207895, 7-(4-Methylpiperazin-1-yl)-4-nitro-2,1,3-benzoxadiazole-1-oxide, 7-(4-Methylpiperazin-1-yl)-4-nitro-1-oxido-2,1,3-benzoxadiazol-1-ium, XI-006
登录查看公司和协议定价
所有图片(2)
About This Item
质量水平
检测方案
≥98% (HPLC)
形式
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
dark red
溶解性
DMSO: 50 mg/mL
运输
ambient
储存温度
2-8°C
SMILES字符串
CN(CC1)CCN1C(C2=[N]([O-])ON=C23)=CC=C3[N+]([O-])=O
一般描述
A cell-permeable benzofuroxan compound that downregulates the p53 negative regulator MDMX protein level in MCF-7, LNCaP, and A549 cells (1 to 10 µM for 16 to 24 h) by suppressesing MDMX promoter transcription activity (IC50 = 2.5 µM in HT1080 cells), leading to enhanced p53 stabilization and activation. A great complement to MDM2 antagonist Nutlin-3 (Cat. Nos. 444143 & 444151) in growth inhibition and apoptosis induction of cancer cells that are more sensitive to MDMX than MDM2 inhibition.
A cell-permeable benzofuroxan compound that is shown to downregulate the p53 negative regulator MDMX protein level in MCF-7, LNCaP, and A549 cells (1 to 10 µM for 16 to 24 h) by suppressesing MDMX promoter transcription activity (IC50 = 2.5 µM in HT1080 reporter assays), leading to enhanced p53 stabilization/activation and an upregulation of the p53 downstream gene MDM2 production, which in turn could mediate further cellular MDMX proteolytic degradation. A great complement to MDM2 antagonist Nutlin-3 (Cat. Nos. 444143 & 444151) in growth inhibition of cancer cells that are more sensitive to MDMX than MDM2 inhibition, such as MCF-7 (72% vs. 42% growth inhibition by 5 µM XI-006 and Nutlin-3a, respectively, in 4 days.), where MDMX, but not MDM2, inhibition results in apoptosis induction.
包装
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
重悬
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他说明
Wang, H., et al. 2011. Mol. Cancer Ther.7, 611.
Berkson, R.G., et al. 2005. Int. J. Cancer115, 701.
Berkson, R.G., et al. 2005. Int. J. Cancer115, 701.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
法规信息
监管及禁止进口产品
Rachel G Berkson et al.
International journal of cancer, 115(5), 701-710 (2005-02-25)
Activation of the p53 tumour suppressor is predicted to have therapeutically beneficial effects. Many current anti-cancer therapies activate the p53 response via DNA damage. Non-genotoxic activation of the p53 pathway would open the way to long-term and possibly prophylactic treatments.
Divya Venkatesh et al.
Genes & development, 34(7-8), 526-543 (2020-02-23)
MDM2 and MDMX, negative regulators of the tumor suppressor p53, can work separately and as a heteromeric complex to restrain p53's functions. MDM2 also has pro-oncogenic roles in cells, tissues, and animals that are independent of p53. There is less
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门